# Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia

Source: https://onco.cc/trials/nct04075292/  
OnCo record `nct04075292` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Acalabrutinib, Rituximab and Chlorambucil in chronic lymphocytic leukaemia, run by AstraZeneca, active and no longer recruiting.

## Summary

Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia is a phase 3 interventional study registered as NCT04075292 by AstraZeneca, with 155 participants enrolled, started 2020-01-20 and due to reach its primary completion in 2024-01-03. Interventions recorded: Acalabrutinib, Rituximab and Chlorambucil. Results have been posted on the registry.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04075292
- Phase: 3
- Setting: A Randomized, Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Acalabrutinib Versus Chlorambucil Plus Rituximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia
- Sponsor: AstraZeneca
- Enrolled: 155

## Sources

- ClinicalTrials.gov NCT04075292: https://clinicaltrials.gov/study/NCT04075292

## Connected records

- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/)
- drugs: [Acalabrutinib](https://onco.cc/drugs/acalabrutinib/), [Chlorambucil](https://onco.cc/drugs/chlorambucil/), [Rituximab](https://onco.cc/drugs/rituximab/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct04075292.json